查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1762314

前列腺癌症生物標記市場，規模，佔有率，產業分析報告:類別，各用途，各最終用途，各地區，2025年～2034年的市場預測

Prostate Cancer Biomarker Market Size, Share, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By Application, By End Use, and By Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 129 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，前列腺癌生物標記市場規模預計到 2034 年將達到 155.8 億美元。本研究報告深入分析了當前的市場動態，並分析了未來的市場成長。

前列腺癌生物標記是從體液和組織中提取的分子指標，有助於識別前列腺癌的存在、分期和進展。人工智慧等多組學方法在基因組學、蛋白質組學和代謝組學中的應用，提高了診斷準確性和疾病分層，進一步推動了市場需求。這些廣泛的分析技術能夠發現具有更高靈敏度和特異性的新型生物標記物，從而支持更準確的患者分類和個人化治療策略。隨著個人化癌症治療日益受到重視，多組學驅動的生物標記平台在臨床和研究環境中的應用正變得越來越重要。

非侵入性和微創診斷技術的進步正在推動市場發展。液體活檢因其能夠透過血液或尿液樣本檢測和監測前列腺癌而日益受到關注，為傳統組織活檢提供了一種更安全、更便捷的替代方案。這些方法提高了患者的依從性，並允許即時監測病情和調整治療方案。隨著醫療保健系統優先考慮早期檢測和微創診斷，對此類創新技術的需求也日益增長，這進一步強化了先進生物標記技術在前列腺癌管理轉型中的作用。

前列腺癌生物標記市場報告重點

按類型劃分，蛋白質生物標記在2024年佔據了最大的市場佔有率，這得益於其廣泛的臨床應用以及在多個疾病管理階段的完善驗證。

從應用角度來看，伴隨診斷領域預計將以最快的速度成長，這得益於個人化治療方法和精準醫療的日益普及。

預計到2024年，北美將在前列腺癌生物標記市場中佔據最大的收入佔有率，這得益於完善的醫療保健體系、日益增長的疾病意識以及診斷和生物製藥公司的聚集。

預計亞太市場將在預測期內實現最快的市場成長，這得益於醫療保健知識的提高、市場診斷能力的提升以及新興國家癌症發病率的上升。

全球主要市場參與者包括Arquer Diagnostics、Beckman Coulter、Bio-Techne、DiaCarta、Exact Sciences Corporation、ExoDx、Genomic Health、GenPath Oncology、MDxHealth、Myriad Genetics、Nucleix、OPKO Health、Proteomedix和Veracyte。

目錄

第1章 簡介

第2章 摘要整理

第3章 調查手法

第4章 全球前列腺癌症生物標記市場洞察

  • 市場概述
  • 前列腺癌症生物標記市場動態
    • 促進因素和機會
      • 攝護腺癌發生率上升及人口老化
      • 生物標記技術的進步
    • 阻礙因素與課題
      • 生物標記開發和檢測成本高昂
    • 公眾輿論與隱私案例法
  • PESTEL分析
  • 前列腺癌症生物標記市場趨勢
  • 價值鏈分析

第5章 全球前列腺癌症生物標記市場:類別

  • 主要調查結果
  • 簡介
  • 遺傳基因生物標記
  • 蛋白質生物標記
  • 細胞為基礎的生物標記
  • 代謝體學生物標記

第6章 全球前列腺癌症生物標記市場:各用途

  • 主要調查結果
  • 簡介
  • 篩檢早與期發現
  • 診斷與風險層化
  • 預後和治療的監測
  • 伴隨式診斷

第7章 全球前列腺癌症生物標記市場:各最終用途

  • 主要調查結果
  • 簡介
  • 醫院及診斷檢驗室
  • 學術研究機關
  • 生物醫藥品企業

第8章 全球前列腺癌症生物標記市場:各地區

  • 主要調查結果
  • 簡介
    • 前列腺癌症生物標記市場分析:各地區，2020～2034年
  • 北美
    • 北美:類別，2020～2034年
    • 北美:各用途，2020～2034年
    • 北美:各最終用途，2020～2034年
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲:類別，2020～2034年
    • 歐洲:各用途，2020～2034年
    • 歐洲:各最終用途，2020～2034年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 亞太地區:類別，2020～2034年
    • 亞太地區:各用途，2020～2034年
    • 亞太地區:各最終用途，2020～2034年
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 中東·非洲
    • 中東·非洲:類別，2020～2034年
    • 中東·非洲:各用途，2020～2034年
    • 中東·非洲:各最終用途，2020～2034年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲
  • 南美
    • 南美:類別，2020-2034年
    • 南美:各用途，2020～2034年
    • 南美:各最終用途，2020～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美國家

第9章 競爭情形

  • 擴大和收購的分析
    • 擴大
    • 收購
  • 聯盟/合作/協定/公開

第10章 企業簡介

  • AlterG, Inc.
  • Biodex Medical Systems, Inc.
  • Caremax Prostate Cancer Biomarker Ltd.
  • DJO Global
  • Drive DeVilbiss Healthcare
  • Ekso Bionics
  • GF Health Products, Inc.
  • Hocoma AG
  • Hospital Equipment Mfg. Co
  • Invacare Corporation
  • Maddak, Inc.
  • Ottobock
  • Patterson Medical(now Ability Dynamics)
  • Rifton Equipment
  • TheraBand(Performance Health)
Product Code: PM5692

The prostate cancer biomarkers market size is expected to reach USD 15.58 billion by 2034, according to a new study by Polaris Market Research. The report "Prostate Cancer Biomarker Market Share, Size, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By application, By End Use, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Prostate cancer biomarkers are molecular indicators derived from bodily fluids or tissues that aid in identifying the presence, stage, or progression of prostate cancer. The integration of multi-omics approaches such as AI in genomics, proteomics, and metabolomics to improve diagnostic precision and disease stratification further boosts the market demand. These wide profiling techniques allow the discovery of novel biomarkers with greater sensitivity and specificity, supporting more accurate patient categorization and tailored treatment strategies. The adoption of multi-omics-driven biomarker platforms is becoming increasingly central to clinical and research settings as the focus on individualized cancer care intensifies.

The advancement of noninvasive and minimally invasive diagnostic techniques is boosting the market development. Liquid biopsies are gaining traction for their ability to detect and monitor prostate cancer using blood or urine samples, offering a safer and more convenient alternative to traditional tissue biopsies. These methods improve patient compliance and allow for real-time disease monitoring and therapy adjustment. The demand for such innovations continues to grow as healthcare systems prioritize early detection and less invasive diagnostics, reinforcing the role of advanced biomarker technologies in transforming prostate cancer management.

Prostate Cancer Biomarker Market Report Highlights

In terms of type, the protein biomarkers segment accounted for the largest market share in 2024, supported by their extensive clinical applications and well-established validation across multiple disease management phases.

Based on application, the companion diagnostics segment is anticipated to experience the most rapid expansion, propelled by growing implementation of personalized treatment approaches and precision therapies.

In 2024, North America maintained the largest revenue share of the prostate cancer biomarker market, owing to its sophisticated healthcare systems, elevated disease awareness, and concentration of diagnostic and biopharmaceutical firms.

The Asia Pacific market is projected to achieve the fastest market growth during the forecast period, driven by improving healthcare knowledge, developing diagnostic capabilities, and increasing cancer prevalence in emerging nations.

A few global key market players include Arquer Diagnostics; Beckman Coulter, Inc.; Bio-Techne; DiaCarta; Exact Sciences Corporation; ExoDx; Genomic Health; GenPath Oncology; MDxHealth; Myriad Genetics, Inc.; Nucleix; OPKO Health, Inc.; Proteomedix; and Veracyte, Inc.

Polaris Market Research has segmented the prostate cancer biomarker market report on the basis of type, application, end use, and region:

By Type Outlook (Revenue, USD Billion, 2020-2034)

Genetic Biomarkers

Protein Biomarkers

Cell-based Biomarkers

Metabolomic Biomarkers

By Application Outlook (Revenue, USD Billion, 2020-2034)

Screening and Early Detection

Diagnosis and Risk Stratification

Prognosis and Treatment Monitoring

Companion Diagnostics

By End Use Outlook (Revenue, USD Billion, 2020-2034)

Hospitals & Diagnostic Laboratories

Academic & Research Institutes

Biopharmaceutical Companies

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Prostate Cancer Biomarker Market Insights

  • 4.1. Prostate Cancer Biomarker Market - Market Snapshot
  • 4.2. Prostate Cancer Biomarker Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Prevalence of Prostate Cancer and Aging Populations
      • 4.2.1.2. Advancements in Biomarker Technologies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Biomarker Development and Testing
    • 4.2.3. Public opinion and privacy legal precedents
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Prostate Cancer Biomarker Market Trends
  • 4.6. Value Chain Analysis

5. Global Prostate Cancer Biomarker Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • 5.3. Genetic Biomarkers
    • 5.3.1. Global Prostate Cancer Biomarker Market, by Genetic Biomarkers, by Region, 2020-2034 (USD Billion)
  • 5.4. Protein Biomarkers
    • 5.4.1. Global Prostate Cancer Biomarker Market, by Protein Biomarkers, by Region, 2020-2034 (USD Billion)
  • 5.5. Cell-based Biomarkers
    • 5.5.1. Global Prostate Cancer Biomarker Market, by Cell-based Biomarkers, by Region, 2020-2034 (USD Billion)
  • 5.6. Metabolomic Biomarkers
    • 5.6.1. Global Prostate Cancer Biomarker Market, by Metabolomic Biomarkers, by Region, 2020-2034 (USD Billion)

6. Global Prostate Cancer Biomarker Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • 6.3. Screening and Early Detection
    • 6.3.1. Global Prostate Cancer Biomarker Market, by Screening and Early Detection, by Region, 2020-2034 (USD Billion)
  • 6.4. Diagnosis and Risk Stratification
    • 6.4.1. Global Prostate Cancer Biomarker Market, by Diagnosis and Risk Stratification, by Region, 2020-2034 (USD Billion)
  • 6.5. Prognosis and Treatment Monitoring
    • 6.5.1. Global Prostate Cancer Biomarker Market, by B-Arrestin Functional Assays, by Region, 2020-2034 (USD Billion)
  • 6.6. Companion Diagnostics
    • 6.6.1. Global Prostate Cancer Biomarker Market, by Companion Diagnostics, by Region, 2020-2034 (USD Billion)

7. Global Prostate Cancer Biomarker Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 7.3. Hospitals & Diagnostic Laboratories
    • 7.3.1. Global Prostate Cancer Biomarker Market, by Hospitals & Diagnostic Laboratories, by Region, 2020-2034 (USD Billion)
  • 7.4. Academic & Research Institutes
    • 7.4.1. Global Prostate Cancer Biomarker Market, by Academic & Research Institutes, by Region, 2020-2034 (USD Billion)
  • 7.5. Biopharmaceutical Companies
    • 7.5.1. Global Prostate Cancer Biomarker Market, by Biopharmaceutical Companies, by Region, 2020-2034 (USD Billion)

8. Global Prostate Cancer Biomarker Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Prostate Cancer Biomarker Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Prostate Cancer Biomarker Market - North America
    • 8.3.1. North America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.3.3. North America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.4. Prostate Cancer Biomarker Market - US
      • 8.3.4.1. US: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.3.4.2. US: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.3.4.3. US: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.5. Prostate Cancer Biomarker Market - Canada
      • 8.3.5.1. Canada: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.4. Prostate Cancer Biomarker Market - Europe
    • 8.4.1. Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.4. Prostate Cancer Biomarker Market - UK
      • 8.4.4.1. UK: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.5. Prostate Cancer Biomarker Market - France
      • 8.4.5.1. France: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.6. Prostate Cancer Biomarker Market - Germany
      • 8.4.6.1. Germany: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.7. Prostate Cancer Biomarker Market - Italy
      • 8.4.7.1. Italy: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.8. Prostate Cancer Biomarker Market - Spain
      • 8.4.8.1. Spain: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.9. Prostate Cancer Biomarker Market - Netherlands
      • 8.4.9.1. Netherlands: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.10. Prostate Cancer Biomarker Market - Russia
      • 8.4.10.1. Russia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.11. Prostate Cancer Biomarker Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.5. Prostate Cancer Biomarker Market - Asia Pacific
    • 8.5.1. Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.4. Prostate Cancer Biomarker Market - China
      • 8.5.4.1. China: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.5. Prostate Cancer Biomarker Market - India
      • 8.5.5.1. India: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.6. Prostate Cancer Biomarker Market - Malaysia
      • 8.5.6.1. Malaysia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.7. Prostate Cancer Biomarker Market - Japan
      • 8.5.7.1. Japan: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.8. Prostate Cancer Biomarker Market - Indonesia
      • 8.5.8.1. Indonesia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.9. Prostate Cancer Biomarker Market - South Korea
      • 8.5.9.1. South Korea: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.10. Prostate Cancer Biomarker Market - Australia
      • 8.5.10.1. Australia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.11. Prostate Cancer Biomarker Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.6. Prostate Cancer Biomarker Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.4. Prostate Cancer Biomarker Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.5. Prostate Cancer Biomarker Market - UAE
      • 8.6.5.1. UAE: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.6. Prostate Cancer Biomarker Market - Israel
      • 8.6.6.1. Israel: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.7. Prostate Cancer Biomarker Market - South Africa
      • 8.6.7.1. South Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.8. Prostate Cancer Biomarker Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.7. Prostate Cancer Biomarker Market - Latin America
    • 8.7.1. Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.4. Prostate Cancer Biomarker Market - Mexico
      • 8.7.4.1. Mexico: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.5. Prostate Cancer Biomarker Market - Brazil
      • 8.7.5.1. Brazil: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.6. Prostate Cancer Biomarker Market - Argentina
      • 8.7.6.1. Argentina: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.7. Prostate Cancer Biomarker Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AlterG, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Biodex Medical Systems, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Caremax Prostate Cancer Biomarker Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. DJO Global
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Drive DeVilbiss Healthcare
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Ekso Bionics
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GF Health Products, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Hocoma AG
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Hospital Equipment Mfg. Co
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Invacare Corporation
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Maddak, Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Ottobock
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Patterson Medical (now Ability Dynamics)
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Rifton Equipment
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. TheraBand (Performance Health)
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables:

  • Table 1 Global Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 2 Global Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 3 Global Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 4 North America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 5 North America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 6 North America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 7 US: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 8 US: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 9 US: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 10 Canada: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 11 Canada: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 12 Canada: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 13 Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 14 Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 15 Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 16 UK: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 17 UK: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 18 UK: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 19 France: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 20 France: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 21 France: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 22 Germany: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 23 Germany: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 24 Germany: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 25 Italy: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 26 Italy: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 27 Italy: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 28 Spain: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 29 Spain: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 30 Spain: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 34 Russia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 35 Russia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 36 Russia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 43 China: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 44 China: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 45 China: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 46 India: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 47 India: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 48 India: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 52 Japan: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 53 Japan: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 54 Japan: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 58 South Korea: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 59 South Korea: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 60 South Korea: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 61 Australia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 62 Australia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 63 Australia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 73 UAE: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 74 UAE: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 75 UAE: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 76 Israel: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 77 Israel: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 78 Israel: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 79 South Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 80 South Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 81 South Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 85 Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 86 Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 87 Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 88 Mexico: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 89 Mexico: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 90 Mexico: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 91 Brazil: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 92 Brazil: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 93 Brazil: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 94 Argentina: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 95 Argentina: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 96 Argentina: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Prostate Cancer Biomarker Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Prostate Cancer Biomarker Market, by Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Application
  • Figure 9. Global Prostate Cancer Biomarker Market, by Application, 2024 & 2034 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Prostate Cancer Biomarker Market, by End Use, 2024 & 2034 (USD Billion)